JP2005518398A5 - - Google Patents

Download PDF

Info

Publication number
JP2005518398A5
JP2005518398A5 JP2003556411A JP2003556411A JP2005518398A5 JP 2005518398 A5 JP2005518398 A5 JP 2005518398A5 JP 2003556411 A JP2003556411 A JP 2003556411A JP 2003556411 A JP2003556411 A JP 2003556411A JP 2005518398 A5 JP2005518398 A5 JP 2005518398A5
Authority
JP
Japan
Prior art keywords
dimethoxy
pyrido
rac
hexahydro
isoquinolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003556411A
Other languages
English (en)
Japanese (ja)
Other versions
JP4197650B2 (ja
JP2005518398A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2002/014685 external-priority patent/WO2003055881A1/en
Publication of JP2005518398A publication Critical patent/JP2005518398A/ja
Publication of JP2005518398A5 publication Critical patent/JP2005518398A5/ja
Application granted granted Critical
Publication of JP4197650B2 publication Critical patent/JP4197650B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2003556411A 2001-12-27 2002-12-20 ＤＰＰ−ＩＶインヒビターとしてのピリド（２，１−ａ）イソキノリン誘導体 Expired - Lifetime JP4197650B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01130882 2001-12-27
PCT/EP2002/014685 WO2003055881A1 (en) 2001-12-27 2002-12-20 Pyrido(2,1-a)isoquinoline derivatives as dpp-iv inhibitors

Publications (3)

Publication Number Publication Date
JP2005518398A JP2005518398A (ja) 2005-06-23
JP2005518398A5 true JP2005518398A5 (enExample) 2005-12-22
JP4197650B2 JP4197650B2 (ja) 2008-12-17

Family

ID=8179706

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003556411A Expired - Lifetime JP4197650B2 (ja) 2001-12-27 2002-12-20 ＤＰＰ−ＩＶインヒビターとしてのピリド（２，１−ａ）イソキノリン誘導体

Country Status (27)

Country Link
US (2) US6727261B2 (enExample)
EP (1) EP1461337B1 (enExample)
JP (1) JP4197650B2 (enExample)
KR (1) KR100608428B1 (enExample)
CN (1) CN1310915C (enExample)
AR (1) AR037983A1 (enExample)
AT (1) ATE445615T1 (enExample)
AU (1) AU2002360074B2 (enExample)
BR (1) BR0215396A (enExample)
CA (1) CA2471262C (enExample)
DE (1) DE60234050D1 (enExample)
ES (1) ES2331354T3 (enExample)
GT (1) GT200200286A (enExample)
HR (1) HRP20040556A2 (enExample)
HU (1) HUP0600068A3 (enExample)
IL (2) IL162516A0 (enExample)
MX (1) MXPA04006241A (enExample)
NO (1) NO20043174L (enExample)
NZ (1) NZ533629A (enExample)
PA (1) PA8562801A1 (enExample)
PE (1) PE20030746A1 (enExample)
PL (1) PL371185A1 (enExample)
RU (1) RU2297417C2 (enExample)
TW (1) TWI265163B (enExample)
UY (1) UY27605A1 (enExample)
WO (1) WO2003055881A1 (enExample)
ZA (1) ZA200404926B (enExample)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03007349A (es) * 2001-02-24 2003-12-04 Boehringer Ingelheim Pharma Derivados de xantina, su preparacion y su empleo como medicamentos.
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
KR20050122220A (ko) 2003-03-25 2005-12-28 다케다 샌디에고, 인코포레이티드 디펩티딜 펩티다제 억제제
WO2004098591A2 (en) 2003-05-05 2004-11-18 Probiodrug Ag Inhibitors of glutaminyl cyclase and their use in the treatment of neurological diseases
EP1625122A1 (en) 2003-05-14 2006-02-15 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
DK1638970T3 (da) * 2003-06-20 2011-01-03 Hoffmann La Roche Pyrid (2, 1-A)-isoquinolinderivater som DPP-IV-inhibitorer
AU2004251829B2 (en) * 2003-06-20 2009-12-17 F. Hoffmann-La Roche Ag Hexahydropyridoisoqinolines as DPP-IV inhibitors
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
KR20060041309A (ko) 2003-08-13 2006-05-11 다케다 야쿠힌 고교 가부시키가이샤 ４-피리미돈 유도체 및 펩티딜 펩티다제 저해제로서의 그의용도
EP1697342A2 (en) * 2003-09-08 2006-09-06 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7790734B2 (en) 2003-09-08 2010-09-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
AU2004290499C1 (en) 2003-11-03 2011-02-24 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
EP1713780B1 (en) 2004-02-05 2012-01-18 Probiodrug AG Novel inhibitors of glutaminyl cyclase
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EA013427B1 (ru) 2004-03-15 2010-04-30 Такеда Фармасьютикал Компани Лимитед Ингибиторы дипептидилпептидазы
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
JP2008501714A (ja) 2004-06-04 2008-01-24 武田薬品工業株式会社 ジペプチジルペプチダーゼインヒビター
WO2006019965A2 (en) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
KR100917545B1 (ko) * 2004-11-30 2009-09-16 에프. 호프만-라 로슈 아게 당뇨병 치료를 위한 ｄｐｐ-ⅳ 억제제로서의 치환된벤조퀴놀리진
MX2007007434A (es) * 2004-12-20 2007-07-17 Hoffmann La Roche Derivados de 4-aminopiperidina.
EP1828192B1 (en) 2004-12-21 2014-12-03 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
DOP2006000008A (es) * 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
BRPI0607680A2 (pt) * 2005-04-26 2009-09-22 Mitsubishi Tanabe Pharma Corp agente profilático/terapêutico para anormalidades do metabolismo de açúcar/lipìdio
MY152185A (en) 2005-06-10 2014-08-29 Novartis Ag Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
CA2617715A1 (en) * 2005-08-11 2007-02-15 F. Hoffmann-La Roche Ag Pharmaceutical composition comprising a dpp-iv inhibitor
PT1942898E (pt) * 2005-09-14 2011-12-20 Takeda Pharmaceutical Inibidores da dipeptidilpeptidase para o tratamento da diabetes
GEP20135791B (en) * 2005-09-14 2013-03-25 Takeda Pharmaceutical Use of dipeptidyl peptidase inhibitors
CN101360723A (zh) 2005-09-16 2009-02-04 武田药品工业株式会社 制备嘧啶二酮衍生物的方法
TW200745080A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor
TW200745079A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
GB0526291D0 (en) 2005-12-23 2006-02-01 Prosidion Ltd Therapeutic method
EP1999108A1 (en) * 2006-03-28 2008-12-10 Takeda Pharmaceutical Company Limited Preparation of (r)-3-aminopiperidine dihydrochloride
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
AU2007238805B2 (en) * 2006-04-11 2012-04-05 Arena Pharmaceuticals, Inc. Methods of using GPR119 receptor to identify compounds useful for increasing bone mass in an individual
PE20071221A1 (es) * 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
CA2649209A1 (en) 2006-04-12 2007-10-18 Probiodrug Ag Enzyme inhibitors
MX2008014024A (es) 2006-05-04 2008-11-14 Boehringer Ingelheim Int Formas poliformas.
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
WO2007140191A2 (en) 2006-05-23 2007-12-06 Theracos, Inc. Glucose transport inhibitors and methods of use
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
EP2066667B1 (en) * 2006-09-15 2011-08-31 F. Hoffmann-La Roche AG Process for the preparation of pyrido[2,1-a]isoquinoline derivatives comprising optical resolution of an enamine
CA2662419A1 (en) * 2006-09-15 2008-03-20 Stefan Abrecht Process for the preparation of pyrido[2,1-a]isoquinoline derivatives by catalytic asymmetric hydrogenation of an enamine
EP2089383B1 (en) 2006-11-09 2015-09-16 Probiodrug AG 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
TW200838536A (en) * 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
CA2696579C (en) * 2007-08-17 2017-01-24 Boehringer Ingelheim International Gmbh Purine derivatives for use in the treatment of fab-related diseases
JP4809931B2 (ja) 2007-08-23 2011-11-09 セラコス・インコーポレイテッド ベンジルベンゼン誘導体およびその使用方法
US20090163718A1 (en) * 2007-12-19 2009-06-25 Stefan Abrecht PROCESS FOR THE PREPARATION OF PYRIDO[2,1-a] ISOQUINOLINE DERIVATIVES
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
EP2108960A1 (en) 2008-04-07 2009-10-14 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
MX2011000637A (es) 2008-07-15 2011-05-02 Theracos Inc Derivados deuretados de bencilbenceno y metodos de uso.
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
MY164581A (en) * 2008-08-15 2018-01-15 Boehringer Ingelheim Int Purin derivatives for use in the treatment of fab-related diseases
MX2011002558A (es) 2008-09-10 2011-04-26 Boehringer Ingelheim Int Terapia de combinacion para el tratamiento de diabetes y estados relacionados.
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
US8410284B2 (en) 2008-10-22 2013-04-02 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
EP2382216A1 (en) 2008-12-23 2011-11-02 Boehringer Ingelheim International GmbH Salt forms of organic compound
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
CA2772488C (en) 2009-09-11 2018-04-17 Probiodrug Ag Heterocyclic derivatives as inhibitors of glutaminyl cyclase
EP3646859A1 (en) 2009-11-27 2020-05-06 Boehringer Ingelheim International GmbH Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
NZ602312A (en) 2010-03-10 2014-02-28 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
JP2013523819A (ja) 2010-04-06 2013-06-17 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｇｐｒ１１９レセプターのモジュレーターおよびそれに関連する障害の処置
JP5945532B2 (ja) 2010-04-21 2016-07-05 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
AU2011249722B2 (en) 2010-05-05 2015-09-17 Boehringer Ingelheim International Gmbh Combination therapy
WO2011153712A1 (en) 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
CN106975074A (zh) 2010-06-24 2017-07-25 勃林格殷格翰国际有限公司 糖尿病治疗
WO2012018950A1 (en) 2010-08-03 2012-02-09 Beth Israel Deaconess Medical Center Methods and compositions for treatment of metabolic disorders
PH12013500547A1 (en) 2010-09-22 2013-06-10 Arena Pharm Inc Modulators of the gpr119 receptor and the treatment of disorders related thereto
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
PH12013501686A1 (en) 2011-02-25 2017-10-25 Merck Sharp & Dohme Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
US20140018371A1 (en) 2011-04-01 2014-01-16 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145361A1 (en) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145604A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145603A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
PH12014500137A1 (en) 2011-07-15 2017-08-18 Boehringer Ingelheim Int Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
CA2880901A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
RU2015140066A (ru) 2013-02-22 2017-03-30 Мерк Шарп И Доум Корп. Противодиабетические бициклические соединения
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
MX386778B (es) 2015-03-09 2025-03-19 Intekrin Therapeutics Inc Métodos para el tratamiento de enfermedad de hígado graso no alcohólico y/o lipodistrofia.
CN107820496B (zh) * 2015-07-27 2020-11-03 豪夫迈·罗氏有限公司 用于治疗和预防乙型肝炎病毒感染的新的四环4-氧代-吡啶-3-甲酸衍生物
CN105412096A (zh) * 2015-12-15 2016-03-23 上海壹志医药科技有限公司 药根碱的药物用途
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
CA3058806A1 (en) 2017-04-03 2018-10-11 Coherus Biosciences Inc. Ppar.gamma. agonist for treatment of progressive supranuclear palsy
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9322828D0 (en) * 1993-11-05 1993-12-22 Sandoz Ltd Organic compounds
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
JP3794448B2 (ja) 1998-02-16 2006-07-05 塩野義製薬株式会社 ベンゾキノリジジン誘導体を含有するカルボン酸のルテニウム錯体化学発光検出用試薬
DE60229922D1 (de) 2001-03-19 2009-01-02 Novartis Ag Kombinationen, ein antidiarrhoikum und epothilon oder ein epothilonderivat enthaltend

Similar Documents

Publication Publication Date Title
JP2005518398A5 (enExample)
CA2471262A1 (en) Pyrido(2,1-a)isoquinoline derivatives as dpp-iv inhibitors
CA2528784A1 (en) Hexahydropyridoisoquinolines as dpp-iv inhibitors
JP6952695B2 (ja) インフルエンザウイルス複製の阻害剤、その適用方法および使用
JP2017527604A5 (enExample)
CN109415360A (zh) 用于抑制shp2活性的化合物和组合物
JP2006143751A5 (enExample)
JP2007527908A5 (enExample)
JP2020510015A5 (enExample)
JP2002520416A5 (enExample)
KR20200052936A (ko) 과혈당증의 치료에 사용하기 위한 헤테로아릴 치환된 베타-히드록시에틸아민
JP2011516511A5 (enExample)
JP2009538910A5 (enExample)
JP2022518456A (ja) 置換多環式カルボン酸、その類似体、およびそれらの使用法
JP2010510999A5 (enExample)
JP2007529421A5 (enExample)
JP2020507589A5 (enExample)
JP2009507909A5 (enExample)
JP2013530951A (ja) ヤヌスキナーゼ阻害剤としてのヘテロ環式化合物
JP2017527605A5 (enExample)
JP2002535401A5 (enExample)
JP2019515908A5 (enExample)
JP2007529528A5 (enExample)
TW200817402A (en) Substituted pteridines
JP2011506501A5 (enExample)